View More Recent Stories
-
Citi Upgrades Glaukos Corporation (GKOS) to Buy
-
UBS Starts Glaukos Corporation (GKOS) at Buy
-
Glaukos Corporation (GKOS) PT Raised to $153 at Stifel
-
Morgan Stanley Downgrades Glaukos Corporation (GKOS) to Underweight
-
Piper Sandler Reiterates Overweight Rating on Glaukos Corporation (GKOS)
-
Needham Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Glaukos Corporation (GKOS) PT Raised to $140 at BTIG
-
Glaukos Corporation (GKOS) Tops Q3 EPS by 20c, provides guidance
-
Glaukos Corporation (GKOS) PT Raised to $155 at Jefferies
-
Truist Securities Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Piper Sandler Reiterates Overweight Rating on Glaukos Corporation (GKOS)
-
Glaukos Corporation (GKOS) Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa
-
BTIG Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
BTIG Reiterates Buy Rating on Glaukos Corporation (GKOS)
-
Glaukos Corporation (GKOS) PT Raised to $145 at Stifel
-
Glaukos Corporation (GKOS) PT Raised to $140 at Piper Sandler
-
Glaukos Corporation (GKOS) PT Raised to $137 at Needham
-
Glaukos Corporation (GKOS) PT Raised to $145 at Truist Securities
-
Glaukos Corporation (GKOS) Reports In-Line Q2 EPS, Beats on Revenue; Offers FY24 Revenue Guidance
-
Glaukos Corporation (GKOS) PT Raised to $141 at Truist Securities
-
Glaukos Corporation (GKOS) PT Raised to $115 at Mizuho
-
MedTech stocks: Q2 earnings season preview
-
Glaukos Corporation (GKOS) to Exchange $230M in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
-
Analyst weighs in on current investor sentiment in MedTech sector

